Overview

• Eli Lilly reports a significant revenue increase to $9.35 billion in Q4, with a 28% year-over-year growth.
• Zepbound, launched in November, generates $175.8 million in sales, while Mounjaro's sales reach $2.21 billion.
• The company's market valuation hits $700 billion, becoming the world's most valuable healthcare company.
• Eli Lilly plans to expand manufacturing capacity to meet the high demand for its weight-loss and diabetes drugs.
• Analysts predict Zepbound sales could reach $1.9 billion in 2024, with potential growth to $12 billion in the coming years.